MTOR and neoplasm: The primary mechanism of this anti-tumor activity is the simultaneous blockade of EGFR and HER2 activation, which downregulated downstream RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways, resulting in G0/G1 arrest in cells.